celf3 Antibody

What is CELF3 and why is it important in research?

CELF3 (also known as Tnrc4, Brunol1, CAGH4, or ERDA4) is a member of the CUG repeat binding protein 1 family of RNA-binding proteins. It plays significant roles in RNA processing and regulation, particularly in neuronal contexts. CELF3 has gained research importance due to its interaction with lncRNA Gomafu and its distinct nuclear localization pattern forming specialized nuclear bodies in neuronal cells . The study of CELF3 is critical for understanding RNA metabolism regulation in neuronal development and function, making CELF3 antibodies essential tools for neurobiology and molecular biology research.

What types of CELF3 antibodies are available for research applications?

Currently, researchers have access to polyclonal antibodies against CELF3, such as rabbit polyclonal antibodies targeting the N-terminal epitope of human CELF3 . These primary, unconjugated antibodies have been validated for multiple applications including Western blotting, immunocytochemistry, immunoprecipitation, and ELISA. While monoclonal antibodies against CELF3 may exist, the search results primarily highlight the efficacy of polyclonal options, which offer advantages in detecting multiple epitopes on the target protein.

How is CELF3 protein typically detected in experimental systems?

CELF3 protein detection employs multiple methodological approaches:

• Western blotting: Using 1:100-500 dilution of anti-CELF3 antibodies to detect multiple isoforms (45, 47, 50, and 52 kDa bands)

• Immunofluorescence/Immunocytochemistry: Visualizing nuclear bodies and cytoplasmic distribution in neuronal cells

• Immunoprecipitation: Isolating CELF3-RNA complexes for analysis of binding partners

• Flow cytometry: Using 1:10-50 dilution for cell-based detection systems

• ELISA: Quantitative detection at 1:1000 dilution

Notably, the 52 kDa band appears relatively weaker in adult brain samples compared to neuroblastoma cell lines, suggesting tissue-specific expression patterns of CELF3 isoforms .

How should researchers optimize Western blot conditions for CELF3 detection?

For optimal Western blot detection of CELF3:

• Sample preparation: Use RIPA buffer supplemented with protease inhibitors to extract total protein from neuronal cells/tissues

• Gel separation: Employ 10-12% SDS-PAGE gels for optimal resolution of the 45-52 kDa bands

• Antibody dilution: Start with 1:250 dilution of anti-CELF3 rabbit polyclonal antibody

• Detection system: Use chemiluminescence with HRP-conjugated secondary antibodies

• Expected patterns: Anticipate multiple bands (45, 47, 50, 52 kDa) representing CELF3 isoforms or processed forms

• Controls: Include knockdown validation controls, as all these bands disappear in CELF3 knockdown samples

The multiple band pattern is due to isoforms or degradation products, but all bands represent specific CELF3 signals as demonstrated by their absence in knockdown experiments .

What procedures are recommended for immunofluorescence detection of CELF3 nuclear bodies?

To successfully visualize CELF3 nuclear bodies (CS bodies):

• Fixation: Use 4% paraformaldehyde (10 minutes) followed by permeabilization with 0.25% Triton X-100 (5 minutes)

• Blocking: Block with 3% BSA in PBS for 30 minutes

• Primary antibody: Apply anti-CELF3 antibody at 1:100 dilution overnight at 4°C

• Secondary antibody: Use fluorophore-conjugated anti-rabbit IgG (1:500) for 1 hour

• Co-localization studies: For CS body identification, co-stain with anti-SF1 antibodies

• Imaging parameters: Acquire z-stack images to capture the full nuclear volume

• Quantification: Measure size (~0.99 ± 0.28 μm) and number (2-3 per nucleus) of CS bodies

Note that harsh FISH treatment can obscure CS body signals, so gentle fixation methods are preferred for co-localization studies .

How can researchers perform CLIP (Cross-linking Immunoprecipitation) analysis with CELF3 antibodies?

For investigating CELF3-RNA interactions through CLIP:

• UV cross-linking: Expose cells to 254 nm UV (400 mJ/cm²) to covalently link protein-RNA complexes

• Lysate preparation: Lyse cells in RIPA buffer with RNase inhibitors

• Partial RNase digestion: Treat with RNase A/T1 to fragment RNA while maintaining protein-bound regions

• Immunoprecipitation: Use anti-CELF3 antiserum with protein A/G beads

• Washes: Perform stringent washes to remove non-specific interactions

• RNA extraction: Extract bound RNA for analysis by qPCR or sequencing

• Controls: Include non-cross-linked samples as negative controls

This approach has revealed that CELF3 preferentially interacts with the middle region of Gomafu lncRNA and also associates with 7SK and Malat1 RNAs .

How do CELF3 nuclear bodies (CS bodies) relate to its functional role in RNA regulation?

CELF3 forms distinct nuclear structures called CS bodies that colocalize with SF1 (another RNA-binding protein) but interestingly do not accumulate Gomafu lncRNA . Research into CS bodies reveals:

These findings suggest that CS bodies may function as specialized RNA processing centers, with CELF3 potentially modulating the function of RNA-binding proteins by sequestering them in separate regions of the nucleus . The size reduction of CS bodies upon knockdown of either CELF3 or SF1 indicates these proteins contribute to body formation without being absolutely required for their existence.

What is known about the relationship between CELF3 and Gomafu lncRNA regulation?

The functional relationship between CELF3 and Gomafu presents an intriguing regulatory mechanism:

• Expression regulation: Knockdown of CELF3 leads to significant downregulation of Gomafu lncRNA

• Binding specificity: CELF3 preferentially interacts with the middle region of Gomafu

• Mechanistic action: CELF3 appears to regulate Gomafu at the transcriptional level rather than affecting its stability

• Spatial organization: Despite interaction, Gomafu and CELF3-containing CS bodies occupy separate nuclear domains

• Functional hypothesis: Gomafu may indirectly modulate RNA-binding protein functions by sequestering these proteins in separate nuclear regions

This suggests a complex regulatory network where CELF3 supports Gomafu expression, while Gomafu potentially acts as a molecular sponge for RNA-binding proteins, indirectly influencing CS body function without colocalizing with these structures.

How might researchers investigate the role of CELF3 in neuronal function and disease models?

To explore CELF3's neuronal functions, researchers could employ these advanced approaches:

• Conditional knockout models: Generate neuron-specific CELF3 knockout mice to assess developmental and behavioral phenotypes

• RNA-seq after CELF3 manipulation: Profile transcriptome changes following CELF3 knockdown/overexpression in neuronal cells

• CLIP-seq analysis: Comprehensively identify CELF3 RNA targets in different neuronal populations

• Proximity labeling: Use BioID or APEX2 fused to CELF3 to identify protein interaction networks within CS bodies

• Live-cell imaging: Employ fluorescently-tagged CELF3 to monitor CS body dynamics in response to neuronal activity

• Correlative disease studies: Examine CELF3 expression/localization in neurological disease models

• Mass spectrometry: Identify post-translational modifications that might regulate CELF3 function

These approaches would help elucidate CELF3's role in RNA metabolism regulation in neuronal contexts and potentially link its dysfunction to specific neurological disorders.

What are common issues when using CELF3 antibodies and how can they be addressed?

Researchers commonly encounter these challenges when working with CELF3 antibodies:

For optimal results, researchers should validate antibody specificity using knockdown or knockout controls, as demonstrated in previous studies where all CELF3 bands disappeared upon knockdown .

What considerations are important when selecting detection methods for CELF3 in different experimental contexts?

When choosing detection methods for CELF3, consider:

• Cell/tissue type specificity: Expression patterns differ between neuroblastoma cell lines and adult brain tissue

• Subcellular localization: CELF3 distributes between cytoplasm and nucleus, with nuclear bodies requiring specific visualization approaches

• Experimental question:

  • For protein-RNA interactions: CLIP analysis is optimal

  • For spatial organization: Immunofluorescence with co-labeling is preferred

  • For quantitative expression: Western blotting or ELISA provides better data

• Technical considerations:

  • For high-throughput screening: Consider cell-based assays or ELISA (1:1000 dilution)

  • For detailed mechanistic studies: CLIP combined with RNA-seq provides comprehensive interaction data

  • For routine detection: Western blotting (1:100-500 dilution) offers reliable results

The selection should be guided by the specific research question while considering the known distribution patterns and biochemical properties of CELF3.

How can researchers validate CELF3 antibody specificity in their experimental systems?

To ensure antibody specificity:

• Knockdown/knockout validation: Perform siRNA knockdown (as in previous studies) or CRISPR knockout of CELF3 and confirm loss of signal

• Multiple antibody comparison: Use antibodies from different sources or against different epitopes

• Blocking peptide control: Pre-incubate antibody with immunizing peptide to demonstrate specific signal reduction

• Recombinant protein control: Use purified CELF3 protein as a positive control in Western blots

• Cross-reactivity testing: Test antibody against related family members (other CELF proteins) to ensure specificity

• Immunoprecipitation-Western blot: Perform IP followed by WB to confirm target protein identity

• Mass spectrometry validation: Following IP, analyze pulled-down proteins by mass spectrometry

The previous development of monoclonal (clone 1E7) and polyclonal antibodies against recombinant CELF3 with knockdown validation provides a model for thorough specificity testing .

What emerging technologies might enhance CELF3 antibody-based research?

Emerging technologies with potential to advance CELF3 research include:

• Bispecific antibodies: Developing dual-targeting antibodies against CELF3 and its binding partners could enable novel co-localization studies and functional analyses

• Cell-free expression systems: Rapid antibody fragment generation and screening could accelerate development of more specific CELF3 antibodies for diverse applications

• Conformation-stabilizing approaches: Developing methods to preserve CELF3's native conformation could improve detection of functionally relevant protein states

• Spatial transcriptomics integration: Combining CELF3 immunostaining with spatial transcriptomics could map protein-RNA interactions in tissue contexts

• Single-cell proteomic approaches: Analyzing CELF3 expression at single-cell resolution could reveal cell-type specific functions

• Multiplexed imaging techniques: Simultaneous visualization of CELF3 with multiple RNA targets could elucidate regulatory networks

• Nanobody development: Smaller antibody fragments could improve nuclear penetration for live-cell imaging of CS bodies

These technological advances could overcome current limitations in studying CELF3's dynamic roles in RNA regulation and nuclear organization.

What are key unanswered questions about CELF3 function that antibody-based research might address?

Critical knowledge gaps that could be addressed through advanced antibody-based research:

• Nuclear body composition: What is the complete protein and RNA composition of CS bodies, and how does it change with cellular state?

• Regulatory mechanisms: How is CELF3 localization and function regulated by post-translational modifications?

• Brain region specificity: Does CELF3 expression and function vary across different neuronal populations?

• Developmental dynamics: How does CELF3 expression change during neuronal development and maturation?

• RNA target specificity: What determines CELF3's RNA binding preferences beyond the middle region of Gomafu?

• Disease associations: Is CELF3 dysregulation associated with specific neurological disorders?

• Functional redundancy: How do other CELF family members compensate for CELF3 function?

Addressing these questions requires the development of more specific antibody tools and integration with complementary molecular and cellular techniques.